The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients

Hepatitis C virus (HCV) eradication is usually associated with dyslipidemia. Most studies in this field have focused on genotype-specific direct-acting antivirals (DAAs), with research on pangenotypic DAAs being limited. This study examined how two pangenotypic DAA regimens, glecaprevir/pibrentasvir...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meng-Yu Ko, Yu-Chung Hsu, Hsu-Heng Yen, Siou-Ping Huang, Pei-Yuan Su
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Series:	Viruses
Subjects:	pangenotypic direct-acting antiviral HCV low-density lipoprotein total cholesterol
Online Access:	https://www.mdpi.com/1999-4915/17/2/263
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-10-01)

Assessment of CD4+ T cell recovery after direct-acting antiviral hepatitis C treatment in HIV/HCV coinfected immunological nonresponders to ART
by: Violetta Vlasova, et al.
Published: (2025-05-01)

Evaluation of direct-acting antiviral agents impact on liver biomarkers in patients with type-2 diabetes and hepatitis C virus infection
by: Irina Duport-Dodot, et al.
Published: (2024-06-01)

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients
by: Sonia Younas, et al.
Published: (2021-10-01)

Evaluation of the risk of developing hepatocellular carcinoma in chronic Hepatitis C patients receiving antiviral treatment
by: Sona Sargsyan, et al.
Published: (2024-05-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status
by: Sylwia Osuch, et al.
Published: (2025-06-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
by: Devis Pascut, et al.
Published: (2020-06-01)

Hepatitis C Infection Confirmation and Fewer Visits Contribute to Improving Treatment Rates in a Predominantly African American Health Center
by: Crisshy Auguste, et al.
Published: (2024-11-01)

Biochemical characterization of a novel purified lectin extracted from Pleurotus ostreatus mushroom for its antiviral activity
by: Yousra A. El-Maradny, et al.
Published: (2025-07-01)

Neuropsychiatric and laboratory outcomes of hepatitis C treatment in an early-treated HIV cohort in Thailand
by: Ferron Ocampo, et al.
Published: (2025-02-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

Direct-Acting-Antivirals Anti-hepatitis C Virus in Renal Transplant Patients: Relevance of Pharmacologic Interaction
by: Maurizio Salvadori, et al.
Published: (2020-08-01)

Use of Hepatitis C Viremic Donors to Expand the Pediatric Donor Pool
by: Natasha Dilwali, et al.
Published: (2024-10-01)

Outcomes of liver transplantation in the era of modern antiviral therapy for hepatitis C
by: K. Yu. Kokina, et al.
Published: (2021-04-01)

Antivirals against HCV infection: the story thus far
by: Ahmad Adebayo Irekeola, et al.
Published: (2022-02-01)

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up
by: S. V. Gavrisheva, et al.
Published: (2023-04-01)

Linking Lipid Profile to Stress Urinary Incontinence in US Women: A National Cross-Sectional Study
by: Lu M, et al.
Published: (2025-06-01)

Association of Lipid Profile with Body Mass Index in Public Employees in Halabja City, Kurdistan Region of Iraq
by: Hardi R. Baqi, et al.
Published: (2020-06-01)

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis
by: Sarah R. Donaldson, et al.
Published: (2025-01-01)

Serum Lipids and Long-Term Antiepileptic Therapy
by: J Gordon Millichap
Published: (1995-07-01)

HCV-related chronic kidney disease in the era of new direct-acting antivirals regimens
by: Jakub Janczura, et al.
Published: (2025-08-01)

Effects of Various Direct-acting Antivirals in the Quality of Life of Patients with Chronic Hepatitis C
by: Hatun ÖZTÜRK ÇERİK, et al.
Published: (2021-12-01)

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C
by: Tom Ryu, et al.
Published: (2025-04-01)

Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?
by: Zhitao Wang, et al.
Published: (2025-07-01)

Hepatitis C Virus Infection in Hemodialysis Patients in the Era of Direct-Acting Antiviral Treatment: Observational Study and Narrative Review
by: Ioana Adela Ratiu, et al.
Published: (2024-12-01)

The Effect of Bisphosphonate Treatment on Blood Lipid Parameters in Patients with Postmenopausal Osteoporosis
by: Canan Tıkız, et al.
Published: (2005-03-01)

Effects of Honey on Some Haematological Indices and Lipid Profile in Male Mice
by: Goji A.D.T. , Tende J.A. , Mohammed, K.A. , Tanko, Y.
Published: (2020-03-01)

Lipid profile of gelded creole horses (Equus caballus) raised in Antabamba-Apurímac
by: Liz Lizbeth Huacho Felix, et al.
Published: (2025-04-01)

The individual empowerment program improves glycemic and lipid controls in admitted type 2 DM patients
by: Ampornpan Theeranut, et al.
Published: (2018-05-01)

Sorafenib-treated hepatocellular carcinoma with or without prior direct-acting antiviral therapy for hepatitis C: outcomes and survival
by: Rania Lithy, et al.
Published: (2025-08-01)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024-11-01)

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
by: Tom Ryu, et al.
Published: (2025-04-01)

Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
by: Lin Zhang, et al.
Published: (2025-02-01)

The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature
by: Olga H. Orasan, et al.
Published: (2019-10-01)

Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank
by: Xi Xiong, et al.
Published: (2024-12-01)

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy
by: Xiping Ran, et al.
Published: (2025-02-01)